Dennis Phillip Andrew 4

What Happened

• Dennis Phillip Andrew, Chief Medical Officer of NovaBridge Biosciences (NBP), converted/ exercised derivative awards on June 17, 2026, resulting in the acquisition of 23,695 ordinary shares (from vested RSUs). On the same day 10,302 shares were surrendered/treated as disposition at $0.00 (tax withholding/settlement). On June 18, 2026 he sold 8,494 ordinary shares in the open market at $0.66 per share for aggregate proceeds of $5,606.
• Net effect: the transactions show a net increase of 4,899 ordinary shares retained by the insider (23,695 acquired minus 10,302 withheld minus 8,494 sold), which is equal to about 2,130 ADSs (using the issuer’s ADS conversion, see below).

Key Details

• Transaction dates: June 17, 2026 (conversion/exercise and withholding), June 18, 2026 (open-market sale).
• Prices and proceeds: open-market sale 8,494 shares @ $0.66 = $5,606. The $0.00 disposition reflects shares used for tax/withholding; acquired shares were from conversion/vesting (no cash purchase price reported).
• ADS conversion: each 10 ADSs represent 23 ordinary shares (1 ADS ≈ 2.3 ordinary shares). The filing notes the equivalent ADS sale price is ~$1.51 per ADS for the open-market sale.
• RSU context: the filings reference restricted stock units (RSUs). Footnotes note a grant on June 17, 2024 that vests over four years, indicating these shares derive from that award.
• Filing timeliness: the Form 4 was filed on June 22, 2026 for transactions on June 17–18, 2026. This appears to be a late filing relative to the normal two-business-day Form 4 deadline.

Context

• These entries are typical of RSU vesting events: vested units converted to shares, a portion withheld to cover taxes/settlement, and a partial open-market sale. The derivative-code activity indicates conversion/exercise rather than a cash purchase. Sales and withholding do not necessarily indicate a change in confidence; they are often routine tax- and liquidity-related actions.